AstraZeneca PLC — Regulatory Filings 2017

May 24, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of May 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

24 May 2017 15:00 BST

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 23 May 2017, it was notified by Mark Mallon, a Person Discharging Managerial Responsibilities of the Company, that, on 23 May 2017, Mr Mallon sold 20,000 American Depositary Shares (ADSs). Two ADSs are equivalent to one ordinary share of $0.25 in the Company.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Mark
Mallon | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Person
Discharging Managerial Responsibilities | |
| b) | Initial
notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description
of the financial instrument, type of instrument Identification
code | AstraZeneca
PLC American Depositary Shares CUSIP:
046353108 | |
| b) | Nature
of the transaction | Sale of
AstraZeneca PLC American Depositary Shares | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | US$
33.900214 | 20,000 |
| d) | Aggregated
information -
Aggregated volume -
Price | Not
applicable - single transaction | |
| e) | Date of
the transaction | 23 May
2017 | |
| f) | Place
of the transaction | NYSE | |

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & M e tabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

| Media Enquiries — Esra
Erkal-Paler | UK/Global | +44 203 749
5638 |
| --- | --- | --- |
| Karen
Birmingham | UK/Global | +44 203 749
5634 |
| Rob
Skelding | UK/Global | +44 203 749
5821 |
| Jacob
Lund | Sweden | +46 8 553 260
20 |
| Michele
Meixell | US | +1 302 885
2677 |
| Investor Relations | | |
| Thomas Kudsk
Larsen | | +44 203 749
5712 |
| Craig
Marks | Finance,
Fixed Income, M&A | +44 7881 615
764 |
| Henry
Wheeler | Oncology | +44 203 749
5797 |
| Mitchell
Chan | Oncology | +1 240
477 3771 |
| Lindsey
Trickett | Cardiovascular
& Metabolic Diseases | +1 240
543 7970 |
| Nick
Stone | Respiratory | +44 203 749
5716 |
| Christer
Gruvris | Autoimmunity,
Neuroscience & Infection | +44 203 749
5711 |
| US toll
free | | +1 866
381 7277 |

Adrian Kemp

Company Secretary, AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

| Date:
24 May 2017 |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break